APTAMERS SPECIFIC FOR TLR-4, AND USE THEREOF Russian patent published in 2019 - IPC C12N15/115 A61P29/00 

FIELD: biotechnologies.

SUBSTANCE: invention relates to the biotechnology. Disclosed is a nucleotide acid aptamer capable of specifically binding and inhibiting TLR-4 and containing a sequence selected from a group consisting of SEQ ID NO: 1 and SEQ ID NO: 2, or its functionally equivalent version, having at least 70 % sequence identity with SEQ ID NO: 1 or SEQ ID NO: 2. Disclosed is a complex capable of specific binding and inhibiting TLR-4, containing an aptamer and a functional group selected from a group consisting of a detectable reagent, a drug and nanoparticles. Disclosed is a method of detecting TLR-4 in a sample in vitro, including i) bringing said sample into contact with aptamer according to any of claims 1–4 or a complex according to any of claims 9–14, and ii) recovering said aptamer or complex not associated with TLR-4, iii) detecting the presence of an aptamer or complex associated with TLR-4 present in said sample. Disclosed is a pharmaceutical composition for treating a pathology characterized by increasing expression of TLR-4, comprising a therapeutically effective amount of at least one aptamer according to any of claims 1–4 or at least one complex as per any of claims 9–14, optionally in combination with one or more pharmaceutically acceptable carrier, excipient or solvent.

EFFECT: invention extends the range of TLR-4 inhibitors.

24 cl, 10 dwg, 6 ex